Abstract
Chimeric antigen receptor modified T cells (CAR-T) therapy plays a key role in the treatment of relapsed/refractory hematological malignancies. And the efficacy of such promising therapy is influenced by many factors, including the production, expansion and lethality of CAR-T cells, the kinds and status of diseases, as well as conditioning regimens. Conditioning regimens such as lymphodepleting prior to CAR-T cells infusion are one of good help to enhance the efficacy of CAR-T therapy. Chemothrapy with cyclophosphamide, fludarabine, pentostatin, bendamustine and cytarabine, as well as total body irradiation (TBI) are main conditioning regimens of CAR-T therapy. However, the optimal selection of conditioning regimens, the optimal dose are still uncertain. This article reviews the current status and research progress of conditioning regimens in CAR-T therapy, in order to find the best scheme and improve the efficacy of CAR-T therapy. Key words: Hematologic neoplasms; Transplantation conditioning; T-lymphocytes; Radiotherapy; Chimeric antigen receptor modified T cells
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Blood Transfusion and Hematology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
